These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 36091003)

  • 61. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.
    Xie L; Xu J; Sun X; Guo W; Gu J; Liu K; Zheng B; Ren T; Huang Y; Tang X; Yan T; Yang R; Sun K; Shen D; Li Y
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376724
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Camrelizumab combined with apatinib for unresectable, metastatic esophageal squamous cell carcinoma: a single-center, single-arm, prospective study.
    Qu Y; Munire A; Zhou N; Saifuding K; Bulibu J; Wang W; Tang X; Li N; Li J; Wang P; Tang Y
    J Gastrointest Oncol; 2024 Feb; 15(1):1-11. PubMed ID: 38482217
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial.
    Li G; Shu B; Zheng Z; Yin H; Zhang C; Xiao Y; Yang Y; Yan Z; Zhang X; Yang S; Li G; Dong J
    Front Oncol; 2022; 12():1051916. PubMed ID: 36505833
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203).
    Han C; Ye S; Hu C; Shen L; Qin Q; Bai Y; Yang S; Bai C; Zang A; Jiao S; Bai L
    Front Oncol; 2021; 11():684867. PubMed ID: 34327136
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial.
    Yu Z; Cai X; Xu Z; He Z; Lai J; Wang W; Zhang J; Kong W; Huang X; Chen Y; Shi Y; Shi X; Zhao Z; Ni M; Lin X; Chen S; Wu X; Chen W; Song Z; Huang C
    Oncologist; 2020 Nov; 25(11):e1640-e1649. PubMed ID: 32533785
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
    Ruan X; Liang JH; Pan Y; Cai R; Zhang RJ; He Z; Yang X; Niu Z; Jiang W
    Cancer; 2021 Sep; 127(17):3163-3171. PubMed ID: 34043812
    [TBL] [Abstract][Full Text] [Related]  

  • 68. SIB-IMRT combined with apatinib for unresectable hepatocellular carcinoma in patients with poor response to transarterial chemoembolization.
    Liu X; Luo J; Zhang L; Yang F; Peng D
    Clin Res Hepatol Gastroenterol; 2022; 46(6):101897. PubMed ID: 35240318
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
    Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
    JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center.
    Ju S; Zhou C; Yang C; Wang C; Liu J; Wang Y; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
    Front Oncol; 2021; 11():835889. PubMed ID: 35174073
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy and safety of sintilimab combined with apatinib as third-line or above therapy for patients with advanced or metastatic gastric cancer.
    Gao L; Tang L; Li X; Peng J; Hu Z; Liu B
    Anticancer Drugs; 2024 Mar; 35(3):277-283. PubMed ID: 37948350
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
    Skof E; Rebersek M; Hlebanja Z; Ocvirk J
    BMC Cancer; 2009 Apr; 9():120. PubMed ID: 19386096
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
    Hu Y; Zhou M; Tang J; Li S; Liu H; Hu J; Ma H; Liu J; Qin T; Yu X; Chen Y; Peng J; Zou Y; Zhang T; Xue J
    Clin Cancer Res; 2023 Oct; 29(20):4088-4097. PubMed ID: 37556120
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial.
    Chen YX; Yang P; Du SS; Zhuang Y; Huang C; Hu Y; Zhu WC; Yu YY; Liu TS; Zeng ZC
    World J Gastroenterol; 2023 Jun; 29(24):3871-3882. PubMed ID: 37426321
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial.
    Verset G; Borbath I; Karwal M; Verslype C; Van Vlierberghe H; Kardosh A; Zagonel V; Stal P; Sarker D; Palmer DH; Vogel A; Edeline J; Cattan S; Kudo M; Cheng AL; Ogasawara S; Daniele B; Chan SL; Knox JJ; Qin S; Siegel AB; Chisamore M; Hatogai K; Wang A; Finn RS; Zhu AX
    Clin Cancer Res; 2022 Jun; 28(12):2547-2554. PubMed ID: 35421228
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study.
    Yang Z; Chen G; Cui Y; Xiao G; Su T; Yu J; Zhang Z; Han Y; Yang K; Jin L
    Cancer Biol Ther; 2019; 20(3):321-327. PubMed ID: 30332553
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma.
    Sun SS; Guo XD; Li WD; Chen JL
    World J Clin Cases; 2024 Jan; 12(2):285-292. PubMed ID: 38313649
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
    Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.